Physician

Katherine Marie Moxley, M.D.

According to 2025 Medicare claims, Katherine Moxley, M.D. (NPI: 1548308448) practices gynecologist/oncologist in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (NPI: 1962876045; TIN: 383983999) and primary practice location at 74146-6236. Moxley is affiliated with the POM ACO (ACO ID: A1297), participating under the MSSP model.

Moxley's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 413 traditional Medicare patients, billed 87,764 HCPCS/CPT codes, and received $1,536,066 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 514 prescription claims across 157 beneficiaries totaling $25,964 in drug costs, led by Eliquis (Apixaban). 2022 DME data shows 24 claims. Open Payments data shows 22 records totaling $9,260. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $790,253 and ending at $1,536,066. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $34,516 and ending at $25,964. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	463	58,842	$790,253
2016	608	87,711	$1,584,787
2017	587	101,537	$1,987,334
2018	264	22,559	$384,307
2019	138	572	$88,284
2020	183	782	$110,884
2021	149	483	$74,133
2022	125	376	$47,826
2023	302	43,448	$606,114
2024	413	87,764	$1,536,066

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	80	412	$34,516
2016	72	382	$13,552
2017	88	387	$22,138
2018	63	388	$37,914
2019	56	342	$45,266
2020	71	316	$14,469
2021	76	338	$173,454
2022	76	255	$214,374
2023	122	364	$8,535
2024	157	514	$25,964

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	38	$1,929
2021	N/R	80	$3,980
2022	N/R	24	$917
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	110	201	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	76	141	$84
96367	Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less	96	293	$20
99459	Pelvic exam	89	134	$15
J1100	Injection, dexamethasone sodium phosphate, 1 mg	78	1,506	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	19	661	$12,705
Estradiol	Estradiol	43	2,650	$1,973
Megestrol Acetate	Megestrol Acetate	22	758	$1,020
Ondansetron Hcl	Ondansetron Hcl	38	380	$531
Prochlorperazine Maleate	Prochlorperazine Maleate	39	421	$412

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$7,990	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$1,270	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Katherine Marie Moxley, M.D.?

Tedicare shows public-source Medicare data for Katherine Marie Moxley, M.D. (NPI 1548308448), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Katherine Marie Moxley, M.D. have ACO affiliation data?

Katherine Marie Moxley, M.D. is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297).

What billing organization is linked to Katherine Marie Moxley, M.D.?

Katherine Marie Moxley, M.D. is linked to OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (billing NPI 1962876045) in the available physician profile data.

Does Katherine Marie Moxley, M.D. have Open Payments data?

Katherine Marie Moxley, M.D. has 22 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.